Brief: Opthea Phase 2B Trial Results Of Opt-302 In Combination With Lucentis® For Wet AMD Published In The Journal Ophthalmology
13/02/2023 11:39
Feb 13 (Reuters) - Opthea Ltd OPT.AX :
* OPTHEA PHASE 2B TRIAL RESULTS OF OPT-302 IN COMBINATION
WITH
LUCENTIS® FOR WET AMD PUBLISHED IN THE JOURNAL OPHTHALMOLOGY
Source text for Eikon: ID:nGNX37gh7Q
Further company coverage: OPT.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Opthea
See all newsBrief: Opthea To Recommence Trading On ASX On Or Around June 3, 2026
Brief: Opthea Says Hamish George Assumes Role Of CFO
Brief: Opthea Logs FY Prelim Loss Attributable $162.8 Mln
Australia's Opthea cuts 80% staff, key executives to exit in deal to avert bankruptcy (updated)
Brief: Opthea Says CEO Fred Guerard To Step Down